-
Cotation en bourse
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLire la suiteTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLire la suiteEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLire la suiteEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lire la suiteThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lire la suiteShaping capital markets for future generations
Curetis
11/11/2015
Curetis celebrates dual listing on Euronext Amsterdam and Euronext Brussels
EnterNext, the Euronext subsidiary designed to promote and grow the market for SMEs, today celebrates the listing of Curetis. Trading in Curetis’ shares started this morning on Euronext Amsterdam and Euronext Brussels under the ticker code CURE.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases.
Oliver Schacht, CEO of Curetis said: “The IPO is a major milestone in Curetis´ corporate history and we are proud to join the group of renowned healthcare companies listed on Euronext. The proceeds of the transaction will mainly be used to expand the commercialization of our Unyvero Platform and to expand our product portfolio to address additional infectious diseases.”
For more information: www.curetis.com